Corneal Epithelial Allograft From Living-related Donor for LSCD

• Sponsor: Chunxiao Wang (Other)
• Overall Status: Completed
• CT.gov ID: NCT03217435
• Collaborator: (none)
• Enrollment: 20
• Location: 1
• Arms: 2
• Actual Duration (Months): 27.6
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

The purpose of the study is to explore whether femtosecond laser-assisted corneal epithelial allograft from living-related donor is more effective than limbal conjunctival allograft from living-related donor for ocular surface reconstruction in patients with limbal stem cell deficiency (LSCD).

Condition or Disease	Intervention/Treatment	Phase
Limbal Stem Cell Deficiency	Procedure: Corneal epithelial allograft; Procedure: Limbal conjunctival allograft; Device: Femtosecond laser; Device: Diamond knife	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 20 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Non-randomized Controlled Clinical Trial of Epithelial Allograft Transplantation From Living-related Donors for the Treatment of Limbal Stem Cell Deficiency
• Actual Study Start Date: Jul 27, 2017
• Actual Primary Completion Date: Nov 13, 2019
• Actual Study Completion Date: Nov 13, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cornea epithelial allograft Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)	Procedure: Corneal epithelial allograft; A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.; Device: Femtosecond laser; A commercial femtosecond laser to create a particular shaped graft for transplantation
Active Comparator: Limbal conjunctival allograft Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)	Procedure: Limbal conjunctival allograft; A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.; Device: Diamond knife; A diamond knife to create a particular shaped limbal graft for transplantation

Outcome Measures

Primary Outcome Measures

1. Restoration of corneal surface in the recipient [1 year]

   Restoration of a completely epithelized, stable, and avascular corneal surface in the recipient

2. Restoration of corneal surface in the donor [1 year]

   Restoration of a completely epithelized, stable, and avascular corneal surface in the donor

Secondary Outcome Measures

1. Uncorrected and best-corrected visual acuity of recipients and donors [1 year]

   To assess changes of uncorrected and best-corrected visual acuity using ETDRS chart.

2. Corneal power, astigmatism and aberration of recipients and donors [1 year]

   To measure changes of corneal power, astigmatism and aberration using autorefractor keratometer and wavefront aberrometer respectively.

3. Corneal sensation of recipients and donors [1 year]

   To measure corneal sensation using Cochet-Bonnet esthesiometer.

4. Corneal thickness of recipients and donors [1 year]

   To measure corneal thickness using Anterior Segment Optical Coherence Tomograph (AS-OCT).

5. Density of stromal nerve and stromal keratocytes of recipients and donors [1 year]

   To measure density of stromal nerve and stromal keratocytes using in vivo confocal microscopy

6. Reconstruction of limbal palisades of Vogt of recipients [1 year]

   To assess reconstruction of limbal palisades of Vogt using in vivo confocal microscopy.

7. Corneal graft rejection of recipients [1 year]

   To assess corneal graft rejection using slit-lamp microscopy.

8. Corneal haze of recipients and donors [1 year]

   To assessing corneal haze using in vivo confocal microscopy

Eligibility Criteria

Criteria

• Ages Eligible for Study: 14 Years to 80 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. LSCD secondary to ocular burns, with the duration of disease of at least 24 months at the time of screening visit;

2. Presence of superficial neo-vascularization affecting at least 2 cornea quadrants and involving central cornea;

3. Having a human leukocyte antigen (HLA)-matched living-related donor (≥4/6 HLA-A/B/DR matched);

4. Informed consent signed by patient or legal guardian. Having the ability to comply with study assessments for the full duration of the study.

Exclusion Criteria:

Recipients:

1. LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement;

2. LSCD by ocular surface disorders other than ocular burn;

3. Eyelids malposition;

4. The center corneal thickness<450µm, the depth of corneal opacity > 150µm;

5. High myopia with a spherical equivalent of -15.0 D or less;

6. Corneal or ocular surface infection within 30 days prior to study entry;

7. Ocular surface malignancy;

8. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;

9. Renal failure with creatinine clearance< 25ml/min;

10. Alanine aminotransferase > 40IU/L, or aspartate aminotransferase > 40IU/L;

11. Platelet levels < 150,000 or > 450,000 per microliter;

12. Hemoglobin < 12.0 g/dL (male) or < 11.0 g/dL (female);

13. Prothrombin time > 16s and activated partial thrombin time > 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy;

14. Pregnancy (positive test) or lactation;

15. Participation in another simultaneous medical investigation or clinical trial;

16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening;

17. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases;

18. Severe dry eye disease as determined by Schirmer's test < 2mm at least in one eye;

19. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent;

20. Signs of current infection, including fever and treatment with antibiotics;

21. Active immunological diseases;

22. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.

Donors:

1. Cornea diseases (epithelial defects, neovascularization, etc.);

2. Eyelids malposition;

3. The center corneal thickness<450µm, the depth of corneal opacity > 150µm;

4. High myopia with a spherical equivalent of -15.0 D or less;

5. Corneal or ocular surface infection within 30 days prior to study entry;

6. Ocular surface malignancy;

7. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;

8. Renal failure with creatinine clearance< 25ml/min;

9. Alanine aminotransferase > 40IU/L, or aspartate aminotransferase > 40IU/L;

10. Platelet levels < 150,000 or > 450,000 per microliter;

11. Hemoglobin < 12.0 g/dL (male) or < 11.0 g/dL (female);

12. Prothrombin time > 16s and activated partial thrombin time > 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy;

13. Pregnancy (positive test) or lactation;

14. Participation in another simultaneous medical investigation or clinical trial;

15. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening;

16. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases;

17. Severe dry eye disease as determined by Schirmer's test < 2mm at least in one eye;

18. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent;

19. Signs of current infection, including fever and treatment with antibiotics;

20. Active immunological diseases;

21. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity	Guangzhou	Guangdong	China	510000

Sponsors and Collaborators

• Chunxiao Wang

Investigators

• Principal Investigator: Yizhi Liu, M.D.Ph.D., Zhongshan Ophthalmic Center, Sun Yat-sen University
• Principal Investigator: Ting Huang, M.D.Ph.D., Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Chunxiao Wang, Clinical investigator, Sun Yat-sen University
• ClinicalTrials.gov Identifier: NCT03217435
• Other Study ID Numbers: 2017KYPJ057
• First Posted: Jul 14, 2017
• Last Update Posted: Feb 28, 2020
• Last Verified: Feb 1, 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Feb 28, 2020